The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage
Status: | Completed |
---|---|
Conditions: | Atrial Fibrillation |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | January 2014 |
End Date: | May 2014 |
The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis
The objective is to assess the safety and effectiveness of new dabigatran and warfarin
patients diagnosed with NVAF in the US DoD population.
patients diagnosed with NVAF in the US DoD population.
Study Design:
Retrospective
Retrospective
Inclusion criteria:
- Patients must be continuously enrolled in a health plan during the pre-index period;
- Patients must have at least one inpatient, or one physician office visit, emergency
room visit with a diagnosis of AF (ICD-9-CM diagnosis code: 427.31in any position) on
the index date or during the pre-index period;
- Patients must have a prescription for dabigatran or warfarin (this first prescription
will be the index date);
- Patients must be treatment naive from all OAC use prior to first dabigatran or
warfarin prescription;
- Aged 18-89 on the index date;
Exclusion criteria:
- Patients with valvular procedures related to the baseline AF diagnosis will be
excluded;
- Patients with transient causes of AF such as hyperthyroidism, any cardiac surgery,
pericarditis, mycoarditis, pulmonary embolism within 3 months prior to their first
diagnosis of AF;
We found this trial at
1
site
Click here to add this to my saved trials